Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus

Virology

Volumn 314, Issue 1, 2003, Pages 190-195

  Pletnev, Alexander G ^a   St Claire, Marisa ^b   Elkins, Randy ^a   Speicher, Jim ^a   Murphy, Brian R ^a   Chanock, Robert M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BIOQUAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; ENVELOPE PROTEIN; LIVE ATTENUATED CHIMERIC WEST NILE VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; NUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BIOENGINEERING; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; ENVELOPE GENE; GENE DELETION; INFECTION PREVENTION; MEMBRANE; MOLECULE; MUTATION; NONHUMAN; PHENOTYPE; PRECURSOR; PRIMATE; PRIORITY JOURNAL; PROTECTION; RHESUS MONKEY; VIREMIA; WEST NILE FLAVIVIRUS;

DENGUE VIRUS; MACACA MULATTA; PRIMATES; WEST NILE VIRUS;

EID: 0141680269     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00450-1     Document Type: Article

References (23)

1. Arroyo J., Miller C.A., Catalan J., Monath T.P. Yellow fever vector live-virus vaccines West Nile virus vaccine development . Trends Mol. Med. 7:2001;350-354.
2. Blaney J.E., Johnson D.H., Firestone C.Y., Hanson C.T., Murphy B.R., Whitehead S.S. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in Vero cells or human liver cells and attenuated in mice. J. Virol. 75:2001;9731-9740.
3. Blaney J.E., Johnson D.H., Manipon G.G., Firestone C.Y., Hanson C.T., Murphy B.R., Whitehead S.S. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology. 300:2002;125-139.
4. Bray M., Men R., Lai C.J. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type challenge. J. Virol. 70:1996;4162-4166.
5. Burke D.S., Monath T.P. Flaviviruses. Knipe D.M., Howley P.M. Fields Virology fourth ed. Vol I:2001;1043-1125 Lippincott Williams and Wilkins, Philadelphia.
6. Campbell G.L., Marfin A.A., Lanciotti R.S., Gubler D.J. West Nile virus. Lancet. 2:2002;519-529.
7. Provisional surveillance summary of the West Nile virus epidemic - United States, January-November 2002. Morb. Mortal. Wkly. Rep. 51:2002;1129-1133.
8. Diamond M.S., Shrestha B., Marri A., Mahan D., Engle M. B cell and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2003;2578-2586.
9. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., Thumar B., Men R., Lai C.J., Elkins W.R., Chanock R.M., Murphy B.R., Whitehead S.S. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65:2001;405-413.
10. Hanley K.A., Lee J.J., Blaney J.E., Murphy B.R., Whitehead S.S. Paired charge-to- alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuated phenotypes. J. Virol. 76:2002;525-531.
11. Hayes C.G. West Nile Fever. Monath T.P. The Arboviruses Epidemiology and Ecology . Vol. V:1989;59-88 CRC Press, Boca Raton, FL.
12. Lanciotti R.S., Roehring J.T., Deubel V., Smith J., Parker M., Steele K., Crise B., Volpe K.E., Crabtree M.B., Scherret J.H., Hall R.A., MacKenzie J.S., Cropp C.B., Panigrahy B., Ostlund E., Schmitt B., Malkinson M., Banet C., Weissman J., Komar N., Savage H.M., Stone W., McNamara T., Gubler D.J. Origin of the West Nile virus responsible for an outbreak of encephalitis in the Northeastern United States. Science. 286:1999;2333-2337.
13. Lindenbach B.D., Rice C.M. Flaviviridae the viruses and their replication . Knipe D.M., Howley P.M. Fields Virology fourth ed. Vol 1:2001;991-1043 Lippincott Williams and Wilkins, Philadelphia.
14. Monath T.P. Prospects for development of a vaccine against the West Nile virus. Ann. NY Acad. Sci. 951:2001;1-12.
15. Pletnev A.G., Bray M., Huggins J., Lai C.J. Construction and characterization of tick-borne encephalitis/dengue type 4 viruses. Proc. Natl. Acad. Sci. USA. 89:1992;10532-10536.
16. Pletnev A.G., Men R. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. Proc. Natl. Acad. Sci. USA. 95:1998;1746-1751.
17. Pletnev A.G., Karganova G.G., Dzhivanyan T.I., Lashkevich V.A., Bray M. Chimeric Langat/dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus. Virology. 274:2000;26-31.
18. Pletnev A.G., Bray M., Hanley K.A., Speicher J., Elkins R. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of tick-borne encephalitis virus complex evaluation in rhesus monkeys and in mosquitoes . J. Virol. 75:2001;8259-8267.
19. Pletnev A.G., Putnak R., Speicher J., Wagar E.J., Vaughn D.W. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. USA. 99:2002;3036-3041.
20. Pletnev A.G., Bray M., Lai C.J. Chimeric tick-borne encephalitis and dengue type 4 viruses effects of mutations on neurovirulence in mice . J. Virol. 67:1993;4956-4963.
21. Tolpin M.D., Massicot J.G., Mullinix M.G., Kim H.W., Parrott R.H., Chanock R.M., Murphy B.R. Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo. Virology. 112:1981;505-517.
22. Troyer J.M., Hanley K.A., Whitehead S.S., Strickman D., Karron R.A., Durbin A.P., Murphy B.R. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am. J. Trop. Med. Hyg. 65:2001;414-419.
23. Whitehead S.S., Falgout B., Hanley K.A., Blaney J.E., Markoff L., Murphy B.R. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77:2003;1653-1657.